<p>Over a billion people worldwide have obstructive sleep apnea — a condition where the airway repeatedly collapses during sleep, causing breathing to stop tens or hundreds of times each night. The health consequences are serious: increased risk of heart disease, stroke, diabetes, and premature death. Yet for decades, the only reliable treatment has been a CPAP machine, a device that straps to your face and pumps pressurised air all night. Many people find it intolerable and stop using it within months.</p>
<p>Now a randomised controlled trial published in <em>The Lancet</em> has produced one of the most promising results ever seen for a pharmacological approach to sleep apnea — and the drug behind it isn't even new.</p>
<h2>Sulthiame: An Old Drug With a New Purpose</h2>
<p>Sulthiame has been used in Europe as an epilepsy medication for decades. Researchers at Apnimed noticed that its mechanism — stabilising the brain's breathing control signals — might also prevent the airway collapse that causes sleep apnea. The hypothesis turned out to be correct.</p>
<p>The FLOW trial enrolled 298 adults with moderate to severe sleep apnea across multiple European centres. Participants received either a placebo or one of three doses of sulthiame (100mg, 200mg, or 300mg) once daily for 15 weeks. The primary measure was the apnea-hypopnea index (AHI) — essentially, how many times per hour breathing stopped or significantly slowed.</p>
<p>At the highest dose, patients experienced 47% fewer breathing interruptions compared to placebo. Nocturnal oxygen levels improved measurably. Side effects were generally mild and temporary.</p>
<h2>'This Could Change Everything for Patients'</h2>
<p>Sleep specialists have long described an unmet need for a tablet treatment. CPAP is effective but only for those who actually use it — and adherence rates are poor globally. A once-daily pill that achieves comparable results would represent a transformation in how the condition is managed.</p>
<p>"The results are exciting because sulthiame appears to address one of the fundamental biological mechanisms causing sleep apnea," said one of the trial investigators. "This isn't just masking symptoms — it's targeting the neural control of breathing."</p>
<p>The trial is a Phase 2 study, meaning larger Phase 3 trials are still needed before regulatory approval. But Phase 2 results of this magnitude in a disease with so little pharmacological progress are highly significant.</p>
<h2>More Than One Billion People Could Benefit</h2>
<p>The World Health Organization estimates that 936 million adults have moderate to severe sleep apnea globally, with the true total including milder cases likely exceeding a billion. The condition is substantially underdiagnosed — many people don't know they have it until a partner notices they stop breathing at night, or until they develop cardiovascular complications.</p>
<p>For those who are diagnosed, sulthiame — if approved — would represent the first tablet option ever validated by a major randomised trial. Apnimed has announced plans to proceed with Phase 3 studies.</p>
<p><em>Sources: The Lancet · Apnimed · Gizmodo · ScienceAlert · The Week, March 2026</em></p>
